Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01548274

Enrollment

Registered

2012-03-08

Start date

2010-10-31

Completion date

2012-10-31

Last updated

2012-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Keywords

endothelial progenitor cells

Brief summary

The purpose of this study is to evaluate the effects of Sarpogrelate in endothelial progenitor cells of patients with atherosclerosis.

Detailed description

Endothelial progenitor cells play an important role in vasculogenesis and vascular repair. Sarpogrelate, a inhibitor of HT2A, is used an an anti-platelet drug, however, a direct effect in vascular cells is supposed.

Interventions

DRUGSarpogrelate

Sarpogrelate 300mg/day

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with atherosclerosis

Exclusion criteria

* Patients with high risk of bleeding * Patients with pregnancy * Patients with allergic reaction of Salpogrelate

Design outcomes

Primary

Measure	Time frame
The number and function of endothelial progenitor cells	3 months

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026